What can we help you find?
The panel of experts in the management of NETs review the indications and safety data of the somatostatin analogues.
Megan May, PharmD, BCOP, and Daneng Li, MD, review the efficacy and the pivotal trials for the somatostatin analogues in the treatment of NETs.
Experts in the management of NETs discuss how the treatment landscape has evolved.
Paul Ament, PharmD, reviews the guidelines for the prevention of VTE.
A panel of experts share the ISTH recommendation and the pharmacist’s role in helping identify patients at increased risk of VTE.
Panelists review the tools, specifically the Padua and IMPROVE models used to identify VTE risks.
Paul Ament, PharmD, and Charles Mahan, PharmD, RPh, PhC, review the rates of VTE postdischarge from a hospital.
Megan May, PharmD, BCOP, and Daneng Li, MD, discuss when patients with NETs should be considered for active surveillance vs treatment.
Experts in the management of VTE discuss the risks and risk factors for identifying VTE.
A panel of experts share how VTE therapy has evolved over time leading to its prevention in many cases.
Charles Mahan, PharmD, RPh, PhC, makes introductions, and Paul Ament, PharmD, provides an overview of venous thromboembolism [VTE].
Cecilia Lau, RPh, BCOP, APh, provides a definition of neuroendocrine tumors, and Megan May, PharmD, BCOP, shares some of the diagnostic processes for NETs.